An interventional study of Intervention Group: Exercise and education. and Usual Care Only in Kidney Disease, End-Stage, Frailty and Transplant;Failure,Kidney, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.
Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 83rd largest by planned enrollment of the 110 interventional ones that give a count, is one of 8 that started in 2024, is one of 50 with no phase, reaches primary completion later than 7 of the 27 other live ones, and was the 123rd registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Bodyport Inc. · Sites in Canada, United States
Ages 21+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 45+
Alessandro Doria · Sites in Canada, United States
Ages 18–75
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 25 · Phase 4 11
First in 1996; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 79 across the 110 interventional studies, 109 across the 24 observational. Of the 91 that completed or were terminated, 17 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 134 have an industry lead sponsor. The 10 most frequent:
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
McGill University Health Centre/Research Institute of the McGill University Health Centre has 6 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
9 of the studies in Kidney Failure, Chronic with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05715814Phase 3University Health Network, TorontomeChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis | 2027-05-01 |
| NCT02823821University of SydneyRandomised Evaluation of Sodium Dialysate Levels on Vascular Events | 2026-12 |
| NCT05968391Université de SherbrookeAcetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP) | 2026-12-15 |
| NCT04603014London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sInterdialytic Peritoneal UltraFiltration in HemoDialysis Patients | 2026-12-30 |
| NCT06032208London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sAn Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 134 studies in Kidney Failure, Chronic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this RCT is to address the feasibility of conducting a 12-week virtual pre-habilitation intervention, which includes exercise and education, in kidney transplant candidates. The intervention also includes a 5-month maintenance phase with independent home exercises (maximum of 8 months of intervention/ended early if the participant undergoes a kidney transplant). The main questions it aims to answer are:
Participants in the control group will receive usual outpatient care.
While waiting for kidney transplant, candidates face many challenges related to their physical health. These physical impairments are strongly associated with pre- and post-transplant mortality and morbidity. Pre-habilitation is the process of enhancing patient functional capacity prior to surgery with the objective of improving tolerance for the stressor. In the context of this protocol, pre-habilitation is referring to an exercise-based program with education prior to transplant. Pre-habilitation has been shown to contribute to a reduction of postoperative recovery time and quicker return to functional ability after thoracic and abdominal surgery. There is, however, limited evidence for the effects of pre-habilitation in kidney transplant candidates.
The investigators are following up previous work conducted with a very small (n=8) pilot pre-post study on pre-habilitation (MUHC REB number = 2020-5951) specifically with kidney transplant candidates. The results were encouraging.
The current multicenter pilot randomized controlled trial (RCT) will address the following research question: is it feasible to conduct a full-scale multicenter RCT to assess the comparative effectiveness of a virtual home-based pre-habilitation versus usual care for kidney transplant candidates? The investigators' specific objectives are to: (1) estimate the proportion of screened patients who meet eligibility criteria, (2) estimate the proportion of eligible patients who consent to randomization, (3) estimate the proportion of patients who adhere to the interventions, (4) estimate follow-up completion rates, (5) inform the calculation of sample size requirements for a full-scale RCT and, (6) assess the acceptability of the intervention by the participants. The assessor-blind pilot RCT will be conducted in three hospitals in Canada: MUHC, CHUM and University of Alberta Hospital. Eligible subjects will be randomized 1:1 to receive either i) virtual home-based multimodal pre-habilitation plus usual outpatient care, or ii) usual outpatient care. Participants will be drawn from the transplant clinics at the 3 sites, and the investigators aim to recruit 30 participants (22 of which will be recruited from MUHC over 9 months).
While some of the assessment appointments will be in person, the intervention is virtual so as not to burden the participants with extra hospital visits. The exercise portion of the study will include a 12-week virtual home-based supervised exercise program and a 5-month maintenance phase with independent home exercises (maximum of 8 months of intervention/ended early if the participant undergoes transplantation). Participants in the intervention group will also watch short educational videos about their kidney, assessment and waitlist, surgery and recovery, medication, and their new life after transplantation. Additionally, participants will be provided a document (PDF) of evidence-based strategies to help cope with stress.
Patients in the control group will receive usual outpatient care. All participants in the control group will receive educational resources received by intervention group participants at trial completion.
All participants will undergo a nutrition screening and will complete questionnaires regarding anxiety and depression. The corresponding transplant team will be notified should participants score 'abnormal' on these assessment tools. Additionally, all study participants will be asked questions regarding the following: whether they have had previous nutritional counselling or received any nutritional interventions, whether they have nutritional concerns/needs, whether they face any challenges in maintaining a balanced diet, whether they have had previous psychological counseling as part of the transplant assessment. This information will be collected as part of a needs assessment to inform inclusion of a nutritional and psychological interventions in subsequent trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
An intervention including exercise and education.
Other: Intervention Group: Exercise and education.
The control group will receive usual outpatient care provided to kidney transplant candidates. All participants in the control group will receive educational resources received by intervention group participants at trial completion.
Other: Usual Care Only
* Exercise Intervention: 12-weeks of supervised, individualized virtual exercise sessions, delivered by an accredited kinesiologist. Independent unsupervised sessions start at week 5. After 12 weeks, a 5-month maintenance phase is followed, continuing to exercise three times weekly for 30 minutes per session. * Education: Prior to each zoom session with the kinesiologist (starting on week 2), participants will watch short educational videos. Additionally, participants will be provided a document (PDF) of evidence-based strategies to help cope with stress.
Usual Care for kidney transplant candidates, which may include medical visits, nutrition, and psychological support.
Proportion of screened patients who meet eligibility criteria
Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes.
Time frame: at 12 months
Proportion of eligible patients who consent to randomization
Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes.
Time frame: at 12 months
Proportion of patients who adhere to the interventions
Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes.
Time frame: at 12 months
Rate of follow-up completion as assessed by number of randomized patients completing assessments pre- and post-induction phase.
Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes. Completeness to follow-up will be compared between trial arms.
Time frame: at 12 months
Rate of change in frailty status as assessed by Fried's phenotype method
Frailty status as measured at the timepoints described below will use the Fried's phenotype method, identified by 3 or more of the following criteria. (please see each component outlined as its own outcome measure). 1. Weight loss 2. Weakness will be assessed using the handgrip strength test ith cut-off values provided by the Frailty index to determine weakness. 3. Exhaustion: 4. Slow gait: 5. Low physical activity: Scoring for the Fried Phenotype: Each indicator can have 0 or 1 as a score, resulting in a total of maximum 5 points, where 0 is being robust, 1-2 pre-frail, 3-4 frail and 5 very frail.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Rate of change in bodyweight obtained from electronic medical chart (contributing to frailty status score for Fried's phenotype method).
Weight loss (of \> 10 lbs over 6 months): obtained from the patient or chart.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Rate of change in handgrip strength as assessed by hand dynamometer (contributing to frailty status score for Fried's phenotype method).
Weakness will be assessed using the handgrip strength test (Jamar hydraulic hand Dynamometer). Patients will do six measurements (three times for each hand, with a rest break of 30 seconds between each). The highest measurement will be compared with cut-off values provided by the Frailty index to determine weakness.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Incidence of exhaustion as assessed by Center for Epidemiological Studies Depression (CES-D) (contributing to frailty status score for Fried's phenotype method).
Exhaustion will be measured by self-reported information based on two questions relating to feeling unusually tired and/or weak, taken from the Center for Epidemiological Studies Depression (CES-D) scale.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Rate of change in gait speed as assessed by the 4-metre gait speed test (contributing to frailty status score for Fried's phenotype method).
Slow gait: the 4-meter gait speed test will be used to analyze walking time. Participants will be timed as they walk 4 metres at their usual walking pace.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Rate of change in low physical activity status as assessed by the Rapid Assessment of Physical Activity (RAPA) questionnaire (contributing to frailty status score for Fried's phenotype method).
Low physical activity: energy expenditure weekly rate calculated using the Rapid Assessment of Physical Activity (RAPA) questionnaire; its 7 items assess habits of volume and intensity of weekly exercise. The score will determine whether participants are active or under-active. The scale ranges from 1 (sedentary) to 7 (active). A score of 5 (under-active regular) or less qualifies as low physical activity.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Rate of change in lower-extremity function will be assessed using the short physical performance battery (SPPB).
The short physical performance battery (SPPB) includes 3 brief physical fitness tests contributing to an overall score demarcating level of frailty. The tests include a 4-metre usual pace walk, a five-repetition sit-to-stand test, and balance tests.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Rate of change in functional exercise capacity as assessed by the 6-minute walk test
Functional exercise capacity will be measured using the 6-minute walking test (6MWT), which uses the distance walked within 6 minutes in metres. The 6MWT has been shown to be a reliable and viable alternative to the gold standard test (cardiopulmonary exercise test) in individuals with chronic kidney disease.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Rate of change in Health Related Quality of Life scores as assessed by the Kidney Disease Quality of Life Short Form Instrument (KDQOL-SF)
Kidney Disease Quality of Life Short Form Instrument (KDQOL-SF) is a self-report measure developed for individuals with kidney disease and those on dialysis. It includes both generic (36 items) and disease-specific (43 items) components for the assessment of HRQoL. Life Participation will be assessed using sub-scales of the KDQOL-SF questionnaire which include questions about personal relationships, work, and activities of daily living. The minimum and maximum scores vary by question, as does the scoring for those items. In some of the items, a higher numerical score (5/5) indicates a favourable health state, whereas the opposite is true for other items (1/5) indicates a more favourable health state. The scoring procedure for the KDQOL-SF transforms the numeric values into a 1-100 range, with higher transformed scores reflecting a better quality of life.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant
Changes in nutrition status as assessed by Patient-Generated Subjective Global Assessment (PG-SGA)
Patient-Generated Subjective Global Assessment (PG-SGA) Scale Information: this is a patient-scored questionnaire in which participants will note changes in food intake, appetite changes, and activity levels. This scale ranges from 0 (no problems) to 36 (worst problem), with a higher score reflecting a greater risk for malnutrition. A score of 9 or above indicates a need for nutritional intervention.
Time frame: For those who receive a transplant within study period: baseline and 3-months post-transplant. For those who do not receive a transplant during study period: baseline and 8-months.
Rate of change in body composition as measured by Bioelectrical Impedance
Bioelectrical impedance will measure measure body composition through phase angle for participants from CHUM and MUHC (not UAH). Phase angle will be the measure used, representing the ratio of resistance to reactance, as an angle. This is part of the nutrition assessment/overall nutrition status.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.
Concentration of serum phosphorus (mmol/L)
At the end of the study, biochemistry will be retrospectively obtained from the participant's medical chart for those occurring within 2 weeks of the scheduled assessment dates found below:
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.
Concentration of serum potassium (mmol/L)
At the end of the study, biochemistry will be retrospectively obtained from the participant's medical chart for those occurring within 2 weeks of the scheduled assessment dates found below:
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.
Percentage of serum A1C
At the end of the study, biochemistry will be retrospectively obtained from the participant's medical chart for those occurring within 2 weeks of the scheduled assessment dates found below:
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.
Incidence of anxiety as assessed by Generalized Anxiety Disorder Seven-Item Scale (GAD-7)
Generalized Anxiety Disorder Seven-Item Scale (GAD-7): this is a 7-question self-report questionnaire completed by participants at the timepoints specified below, indicating the possibility of presence of anxiety. The GAD-7 ranges from 0 to 21, with a lower score indicating minimal anxiety, and a higher score indicating severe anxiety.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.
Incidence of depression as assessed by the Patient Health Questionnaire (PHQ-8)
Patient Health Questionnaire (PHQ-8); this is an 8-question self-report questionnaire completed by participants at the timepoints specified below, indicating the possibility of presence of depression. The PHQ-8 ranges from 0 to 24, with a higher score indicating worse health outcomes. Specifically, a score of 3-6/6 for the first 2 questions indicates anxiety, and a score of 3-6/6 on the last 2 questions indicates depression. Higher scores indicate indicate increasing severity of anxiety or depression.
Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.
Level of safety as assessed by number/severity of recorded adverse events related to the intervention
All adverse events will be recorded. Upon review by the investigator, adverse events will be categorized by "related to the intervention" or "unrelated to the intervention" and categorized into three categories: musculoskeletal (e.g., pain, fall), cardiovascular or kidney related. Adverse events will be graded in terms of severity (Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; and Grade 5: Death).
Time frame: from recruitment to end of intervention
Trends identified in post-transplant recovery trajectory as sourced from electronic medical chart information
Information collected will include (1) intensive care unit length of stay, (2) hospital length of stay, (3) number of readmissions to hospital within 3 months after the surgery, (4) discharge destination, (5) allograft function.
Time frame: at 3-month post-transplant
Level of acceptability of the intervention as assessed by quantitative semantic differential scale
Acceptability of the intervention will be assessed in a subset of patients in the intervention group using both quantitative and qualitative data. Quantitative data will include results from a semantic differential scale and from the closed-ended questions of a semi-structured telephone interview (see outcome measure 25). Based on the semantic differential scale, the intervention will be acceptable if a total score of a minimum of 16 is obtained.
Time frame: Post-induction phase (at 12-weeks), and at 8-months
Level of acceptability of the intervention as assessed by qualitative author-generated questionnaire
Acceptability of the intervention will be assessed in a subset of patients in the intervention group using both quantitative and qualitative data. Quantitative data will include results from a semantic differential scale (see outcome measure 23) and from the closed-ended questions of a semi-structured author-generated telephone questionnaire (guided by previous usability/acceptability studies).
Time frame: at 8-months
Plan to share: Yes — Summary results will be available on the trial registry site within 12 months from the last visit of the last participant. Other data will be shared on request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available within 12 months from the last visit of the last participant.
Access criteria: Access to anonymized IPD can be requested by researchers.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Aug 2026, 21 months after the start.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 21 months is close to that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →